Active Ingredient(s): Tisotumab Vedotin-tftv
FDA Approved: * September 20, 2021
Pharm Company: * SEAGEN
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Tivdak Overview

Tisotumab vedotin, sold under the brand name Tivdak is a human monoclonal antibody used to treat cervical cancer.[1] Tisotumab vedotin was approved for medical use in the United States in September 2021.[1][2] Tisotumab vedotin is the international nonproprietary name (INN).[3] References .mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;m...

Read more Tivdak Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tisotumab_vedotin

Recent Tivdak Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Tisotumab Vedotin-tftv
  • Injection: 40mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Tisotumab Vedotin-tftv or a similar ingredient: (1 result)